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Objectives: To evaluate the practice of aminoglycoside use/monitoring in Kenya and explore healthcare worker
(HCW) perceptions of aminoglycoside monitoring to identify gaps and opportunities for future improvements,
given the low therapeutic index of aminoglycosides.
Methods: This was a two-phase study whereby we reviewed patients’ medical records at Kenyatta National
Hospital (October–December 2016) in Phase 1 and interviewed HCWs face to face in Phase 2. Outcome measures
included describing and evaluating the practice of aminoglycoside use and monitoring and compliance to
guidelines. Data were analysed using descriptive and inferential analysis.
Results: Overall, out of the 2318 patients admitted, 192 patients (8.3%) were prescribed an aminoglycoside, of
which 102 (53.1%) had aminoglycoside doses that did not conform to national guidelines. Aminoglycoside-
related adverse effects were suspected in 65 (33.9%) patients. Monitoring of aminoglycoside therapy was per-
formed in only 17 (8.9%) patients, with no therapeutic drug monitoring (TDM), attributed mainly to knowledge
and skill gaps and lack of resources. Out of the 28 recruited HCWs, 18 (64.3%) needed training in how to perform
and interpret TDM results.
Conclusions: The practice of using and monitoring aminoglycosides was suboptimal, raising concerns around po-
tential avoidable harm to patients. The identified gaps could form the basis for developing strategies to improve the
future use of aminoglycosides, not only in Kenya but also in other countries with similar settings and resources.
Introduction
Systemic aminoglycoside antibiotics (gentamicin, amikacin and
tobramycin) are high-risk medicines.1 If not used and monitored
appropriately, aminoglycosides may be associated with serious
adverse effects including permanent hearing loss, vestibular tox-
icity and reversible nephrotoxicity.2–4 Children are more vulnerable
to aminoglycoside toxicity due to reduced clearance.5 For amino-
glycosides, serum creatinine concentrations are used to monitor
possible nephrotoxicity and a baseline serum creatinine concen-
tration should be obtained before initiating therapy. An increase in
serum creatinine of greater than 25%–30% above the baseline,
after ruling out other causes of nephrotoxicity, indicates
aminoglycoside toxicity, requiring a switch to other treatment
alternatives or intense monitoring.3
Despite the need for strategies to monitor its use, neither
therapeutic drug monitoring (TDM) nor treatment protocols for
aminoglycosides are currently available in Kenyatta National
Hospital (KNH), the largest referral hospital in Kenya, apart from
the national Basic Paediatric Protocol (BPP) for the management of
critically ill paediatric patients.6 The pharmacy department in the
hospital intends to introduce a TDM service. However, the opportu-
nities and gaps for implementation of TDM of aminoglycosides at
KNH are unknown. Consequently, the objectives of this study were
to evaluate current prescribing and monitoring of aminoglycosides
VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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in the paediatric wards of KNH, including adherence to the national
protocol, and secondly, to assess the willingness, understanding
and knowledge of healthcare workers (HCWs) regarding TDM of
aminoglycosides in KNH prior to introducing a monitoring service.
Methods
The study consisted of two phases: the first phase was a medication-use re-
view of aminoglycosides in paediatric patients over a 3 month period from
October to December 2016 on the four general paediatric wards (GPWs)
and the newborn unit (NBU) in KNH. This included evaluation of key proc-
esses in the medication-use cycle including prescribing, administration,
monitoring, drug safety issues and patient outcomes. The second phase
was structured interviews with HCWs.
Study cohort and participants
The study cohort for Phase 1 was paediatric patients admitted to the
GPWs/NBU of KNH during the study period who were on any aminoglyco-
side, with ages between 0 and 12 years. Patients were excluded if they
were discharged before recruitment, not on any aminoglycosides during
the period of the study, admitted to paediatric wards other than the GPWs
or the NBU or were older than 12 years. Phase 2 included a structured inter-
view of the HCWs in the GPWs and NBU.
Universal sampling was used. For Phase 1, all the files of patients meet-
ing the inclusion/exclusion criteria were sampled and reviewed. The sam-
pling was done within 48 h after the aminoglycoside was prescribed. Signed
consent to collection of the data was given by the parents/guardians for
children aged ,7 years and both parental consent and child assent was
obtained for children aged 7 years. For Phase 2, paediatrician specialists
(n"40), senior house officers (n"15), pharmacists (n"4), nurses who
were mainly responsible for the paediatric wards (n"6) and laboratory
technicians (n"3) were contacted by phone as well as approached after
completion of their ward rounds and asked to participate in the study.
Sample size determination
In Phase 1, the sample size was calculated using the Cochran formula.7
Based on a previously reported aminoglycoside prevalence of 12.1%,8 a
sample of 164 was estimated. To account for incomplete data, the calcu-
lated sample size was inflated by 10% to target a minimum of 181
patients.
Data collection
A tool was designed to collect information on patient sociodemographic
characteristics, medical history, medications prescribed, prescribing
clinician and patient monitoring, developed by combining the WHO tool on
investigating drug use,9 the NICE audit tool for antibiotics10 and a
gentamicin-specific chart.11 Patient files were reviewed daily and data col-
lection tools updated accordingly. As Phase 1 was an observation study, no
blood samples were ordered/taken from the patients, rather we just
recorded the serum creatinine from the patients’ files; creatinine level
results dated within 48 h from the date of aminoglycoside prescribing were
considered baseline creatinine levels and the others as follow-up creatinine
levels.
In Phase 2, a questionnaire (available as Supplementary data at JAC-
AMR Online) was developed by modifying a sample questionnaire for the
Knowledge, Attitude and Practice (KAP) study on rational drug use by doc-
tors.12 The data collection tools were piloted at one of the KNH paediatric
wards by purposely sampling 10 patients on an aminoglycoside in Phase 1
and two HCWs in Phase 2.
Study outcome measures
The study outcomes were describing and evaluating the practice of pre-
scribing and monitoring aminoglycosides in paediatric wards, as well
as determining the compliance to prescribing the correct aminoglycoside
dosage based on the national BPP recommendations.6 Study covariates
included patients’ ages, gender, weight and diagnosis, and the cadre of
prescriber, antibiotic combinations, comedications, comorbidity and dur-
ation of aminoglycoside therapy. Monitoring of aminoglycoside therapy for
adverse effects was assessed by monitoring serum creatinine levels, with
nephrotoxicity defined as an increase of serum creatinine by .25%
from the baseline creatinine level. Serum creatinine, rather than creatinine
clearance, was used to assess nephrotoxicity due to two main reasons:
first, it is the normal clinical practice to use serum creatinine to assess
aminoglycoside-associated nephrotoxicity, not only in Kenya but also
worldwide, including in the UK;13 secondly, serum creatinine is the only fac-
tor in the creatinine clearance formula that could change quickly, mainly in
response to alteration in renal function during aminoglycoside therapy,
compared with the other factors included in the creatinine clearance for-
mula such as age and height of the child; therefore, any change in serum
creatinine will be reflected directly in the creatinine clearance value. Hence
serum creatinine provides similar information on patients’ renal function.
Furthermore, in a setting with limited resources such as Kenya, it is more
practical and feasible to use serum creatinine as it avoids the staff using a
more complicated equation to calculate creatinine clearance, especially in
view of the high workload pressure and limited number of staff in these
resource-poor settings.
Data analysis
Descriptive statistical analysis and inferential analysis were performed
using the unpaired Student’s t-test for normally distributed continuous vari-
ables or the Mann–Whitney test for non-normally distributed continuous
variables. The v2 test was used for inferential data analysis for categorical
variables. The sign rank test was used to determine whether the median
doses complied with the recommendations in the guidelines. The level of
significance was set at 0.05. The data were analysed using STATA version
13 software.
Ethics
Study approval was obtained from the KNH/University of Nairobi Ethics
Review Committee (approval number P563/07/2016).
Results
Phase 1
Baseline characteristics and prevalence of
aminoglycoside use
A total of 2318 paediatric patients were admitted to the GPWs and
NBU during the study period, of which 192 (8.3%) patients were
prescribed aminoglycosides (Table 1). Out of the 192 eligible
patients, 113 (58.9%) were male and 156 (81.2%) were aged
1 month (Table 1). The patient’s weight was documented in the
majority of patients’ medical records (88%, n"169/192); how-
ever, the weight of a significant number of patients (52.3%,
n"23/44) in the GPWs was not recorded.
Gentamicin was the most commonly used aminoglycoside
(61.5%, n"118/192). The main indication for an aminoglyco-
side was neonatal sepsis (42.2%; n"81/192), followed by sus-
pected infections with a presentation of respiratory distress
(6.8%; n"13/192). A total of 39.6% (n"76/192) had two
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comorbidities and 33.3% (n"64/192) had one medical
condition.
Number and types of medicines co-prescribed with
aminoglycosides
The median total number of medicines per patient, including
aminoglycosides, was 3 (range: 1–8), with 38% (n"73/192) on 2
medicines (Table 2). The median number of antibiotics per patient
was 2 (range: 1–4) with the majority (84.9%; n"163/192) receiv-
ing 2 antibiotics at a time.
Antibiotics co-administered with aminoglycoside
More than half of the patients (55.7%; n"107/192) were started
on gentamicin/benzylpenicillin as the first-line antibiotic combin-
ation (Table 3). Amikacin/ceftazidime was the second most com-
monly prescribed (15.1%; n"29/192) combination. Only 48 (25%)
patients were switched from one antibiotic combination to
another. Out of these, 35.4% (n"17/48) were switched from
gentamicin/benzylpenicillin to amikacin/ceftazidime, followed by
a switch to oral antibiotics (16.7%; n"8/48). Fourteen patients
(7.3%) had oral antibiotics administered with an aminoglycoside,
with erythromycin being the most common (57.1%; n"8/14).
Nephrotoxic drugs were concurrently administered with an
aminoglycoside to 14 patients (7.3%), which included vancomycin
(35.7%; n"5/14), IV furosemide (28.5%; n"4/14), NSAIDs
(21.4%; n"3/14) and aciclovir (14.3%; n"2/14).
Dose and duration of aminoglycoside therapy in
comparison with the national BPP treatment protocol
Although the prescribed mean gentamicin dose for neonates aged
,7 days and weighing2 kg was not significantly different from the
recommended dose in the BPP protocol (3.4 versus 5 mg/kg/day;
P"0.197), only 40.7% (n"24/59) of patients were prescribed the
recommended dose of gentamicin of 5 mg/kg/day, with 37.3%
Table 1. Baseline characteristics of the paediatric patients on aminogly-
cosides at the KNH
Characteristic
Ward, n (%)
GPW NBU total
Total admitted 1407 (60.7) 911 (39.3) 2318 (100)
Total enrolled 44 (3.1) 148 (16.2) 192 (8.3)
Sex
male 22 (11.5) 91 (47.4) 113 (58.9)
female 22 (11.5) 57 (29.7) 79 (41.1)
Age category
0–1 month 11 (5.7) 145 (75.5) 156 (81.2)
.1–24 months 19 (9.9) 3 (1.6) 22 (11.5)
.2–6 years 8 (4.2) 0 (0) 8 (4.2)
.6–12 years 6 (3.1) 0 (0) 6 (3.1)
Table 3. Treatment of the most common infections in the paediatric wards of KNH
Initial antibiotic combination
Health problem, n (%)
severe pneumonia suspected infections with presentation as respiratory distress neonatal sepsis
Benzylpenicillin/gentamicin 5 (26.3) 22 (73.3) 41 (50.6)
Gentamicin only 4 (21) 0 (0) 2 (2.5)
Gentamicin/other antibiotics 0 (0) 0 (0) 1 (1.2)
Amikacin only 1 (5.3) 0 (0) 1 (1.2)
Amikacin/ceftazidime 1 (5.3) 6 (20) 12 (14.8)
Amikacin/meropenem 0 (0) 1 (3.3) 13 (16.0)
Amikacin/ceftriaxone 8 (42.1) 0 (0) 6 (7.4)
Amikacin/vancomycin 0 (0) 0 (0) 1 (1.2)
Amikacin/vancomycin/meropenem 0 (0) 1 (3.3) 0 (0)
Amikacin/other antibiotics 0 (0) 0 (0) 4 (4.9)
Total 19 (100) 30 (100) 81 (100)
Table 2. Medications co-prescribed with aminoglycosides in paediatric wards of KNH
Ward, n (%) Vitamins and supplements Aminophylline Gastrointestinal drugs Analgesics Anticonvulsants Othersa
GPW 13 (6.8) 1 (0.5) 5 (2.6) 9 (4.7) 4 (2.1) 22 (11.5)
NBU 47 (24.5) 22 (11.5) 11 (5.7) 4 (2.1) 9 (4.7) 23 (12.0)
Total 60 (31.3) 23 (12.0) 16 (8.3) 13 (6.8) 13 (6.8) 45 (23.5)
aThe others were tetracycline eye ointment, saline nasal drops, anti-TB drugs, antiretrovirals, anti-opportunistic infection drugs and cardiovascular
drugs.
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(n"22/59) and 22.0% (n"13/59) being underdosed and over-
dosed, respectively. For neonates weighting ,2 kg, the mean dose
was significantly higher than the recommended dose (5 versus
3 mg/kg/day; P"0.006), with only 13.6% (n"3/22) of neonates
prescribed the exact recommended dose and the majority (63.6%;
n"14/22) being overdosed. Among those patients who were not
prescribed the recommended aminoglycoside dose (n" 49), 19
(38.8%) had neonatal sepsis.
For those aged .7 days, the mean gentamicin dose was not
significantly different from the recommended dose (5.2 versus
7.5 mg/kg/day; P"0.068); however, only 14.3% (n"2/14) were
prescribed the exact recommended dose, with the majority
(57.1%, n"8/14) being underdosed, of which 75% (n"6/8)
had neonatal sepsis. Similarly, the prescribed mean amikacin dose
was not significantly different from the recommended dose
of 15 mg/kg/day (P"0.552) for all patients; however, 33.0%
(n"36/109) were underdosed.
In terms of duration of therapy, most of the patients (72.4%,
n"139/192) were on an aminoglycoside for at least 72 h, with
39.6% (n"76/192) treated for at least 7 days. Slightly less than
half (46.9%, n"90/192) of the patients did not complete the
prescribed duration of therapy, mainly due to discharge (32.2%,
n"29/90), change to other antimicrobials (30%, n"27/90) or
death (28.9%, n"26/90).
Administration of aminoglycosides
All the patients received an aminoglycoside as an IV injection once
daily. In all cases, gentamicin and amikacin were administered as
a bolus infusion over 30 s. Half of the patients (49.5%, n"95/192)
received all their daily doses of aminoglycoside within 1 h of the
prescribed administration time; however, 16.7% (n"32/192)
missed some aminoglycoside doses over the treatment course, of
which the majority (59.4%, n"19/32) missed one dose and 28%
(n"9/32) missed two doses. No reason was reported for the
missed dose for the majority of cases (59.4%, n"19/32). Lack of
an IV line was the reported reason in 10 cases (31.3%).
Monitoring of aminoglycoside therapy for adverse effects
Baseline and follow-up creatinine levels stratified by age catego-
ries are presented in Table S1. Baseline creatinine levels were
recorded for the majority of the cases (68.8%, n"132/192), most-
ly for those aged 2 to 6 years (100%, n"9/9), with the least
among those aged 30 days (63.5%, n" 99/156). Among those
patients with baseline creatinine level, 8.3% (n"11/132) had a
documented baseline creatinine level above 120lmol/L. Out of
these 11 patients, aminoglycoside therapy was discontinued after
one dose in 1 patient and after two doses in 2 patients. It was not
documented whether the discontinuation was informed by the
elevated creatinine level or other patient factors.
At least one follow-up creatinine level was measured in only
8.9% (n"17/192) of the patients, mostly in those aged 30 days to
24 months (28.6%, n"6/21), with the least among those aged 2
to 6 years (16.7%, n"1/6) (Table S1). Out of these, 11.8% (n"2/
17) had follow-up creatinine levels above 100lmol/L, while 29.4%
(n"5/17) had an 11.7%–405% increase in their follow-up creatin-
ine level compared with baseline values. Among patients who
were on aminoglycoside therapy for 7 days (n"76), nine
patients (11.8%) had a follow-up creatinine level at least twice a
week. The median baseline creatinine level was 56lmol/L (range:
17–239.7lmol/L). The median follow-up creatinine level was
62.2lmol/L (range: 26–128.3lmol/L). An increase in baseline cre-
atinine level of .30% was observed in one patient only, who
received gentamicin/benzylpenicillin for 2 days then amikacin/cef-
tazidime for 6 days before being changed to meropenem for an-
other 7 days.
Treatment outcome of paediatric patients on
aminoglycoside therapy
The majority of the patients (68.3%, n"131/192) were suc-
cessfully managed with the first-line antibiotic combination
and were discharged without switching to other antimicrobials.
Adverse drug effects were suspected in 33.9% (n"65/192) of
patients. Fever resolved in all 53 patients who were febrile.
Some patients (13.5%, n"26/192) died during the course of
treatment.
Aminoglycoside-related potential adverse drug effects
Some of the suspected aminoglycoside-related adverse drug
effects were nausea and vomiting (12.3%, n"8/65) and electro-
lyte imbalance (7.7%, n"5/65), of which 60% (n"3/5) had hyper-
kalaemia, 20% (n"1/5) had hypokalaemia and 20% (n"1/5) had
hypernatraemia; 80% of them (n" 4/5) were on gentamicin/ben-
zylpenicillin. There was no significant difference in the incidence of
suspected adverse drug effects between males and females [60%
(n"39/65) versus 40% (n"26/65), P"0.790); however, a higher
incidence was observed in the NBU (75.4%, n"49/65).
Summary of medication errors and identified gaps in using
aminoglycosides
The most common type of medication error was a monitoring error
(Table 4). This was followed by wrong dose and wrong time,
respectively.
Phase 2: HCWs’ willingness, understanding and
knowledge of TDM of aminoglycosides in KNH
Participant recruitment and response rate
A total of 28 participants were recruited including 7 paediatrician
specialists (response rate 17.5%; 7/40), 8 senior house officers (re-
sponse rate 53.3%), 4 pharmacists (response rate 100%), 6 nurses
(response rate"100%) and 3 laboratory technologists (response
rate"100%) (Figure 1).
Baseline characteristics
The majority of the participants were female (64.3%, n"18/28),
with a median age of 38.5 years (range: 26–74 years) and a me-
dian duration of practice of 12.5 years (range: 3–45 years).
Current practice for determining aminoglycoside doses
Only a minority of the study participants (17.9%, n"5/28) reported
using existing paediatric protocols and guidelines in determining
aminoglycoside doses, mostly pharmacists (50%, n"2/4) (Table 5).
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Almost half (46.4%, n"13/28) stated they determined the dose
based on weight and age, mostly nurses (66.7%, n"4/6), followed
by senior house officers (62.5%, n"5/8). Four respondents (14.3%)
reported consideration of renal function tests when determining
the dose, mostly pharmacists (50%, n"2/4). The majority (53.6%,
n"15/28) were unsure about current monitoring practices, mainly
laboratory technologists (66.7%, n"2/3); six (21.4%) stated it is not
currently performed and seven (25%) reported using renal function
tests as a method of monitoring aminoglycoside therapy, mainly
senior house officers (50%, n"4/8) (Table 5).
The majority (53.6%, n"15/28) reported lack of a double-check-
ing system before administration of an aminoglycoside, six (21.4%)
were unsure and the remaining seven (25%) reported the existence
of several such double-checking systems, mostly paediatricians
(28.6%, n"2/7) (Table 5), of whom 57.1% (n"4/7) reported a re-
view by the consultants during ward rounds, confirmation by nurses
before administration (14.3%, n"1/28) and cross-checking by
pharmacy staff before issuance of the drugs (28.6%, n"2/28).
Knowledge and experience of TDM for aminoglycosides
Sixteen respondents (57.1%) reported previous experience with
ordering and performing TDM, mostly senior house officers (75%,
n"6/8) (Table 5). Eighteen respondents (64.3%) reported their
need for training on TDM, mostly pharmacists (100%, n"4/4), fol-
lowed by nurses (66.7%, n"4/6) (Table 5). When the respondents
were asked to list medicines they thought would need TDM, ami-
noglycoside was mentioned by half of them (n"14/28).
HCWs’ perception of barriers
When the respondents were asked about whether a treatment
protocol on aminoglycoside dosing and monitoring is needed at
KNH, all affirmed the need. When the study participants were
asked about the content of such protocol, dose calculation and
how to monitor patients were mentioned by 11 (39.3%), followed
by information guidance around aminoglycoside-associated
adverse drug effects (17.9%, n"5/28). In terms of the barriers, a
knowledge gap was reported by 12 participants (42.9%) followed
by a lack of willingness (32.9%, n"9/28) (Figure 2).
Discussion
The study findings demonstrated several issues and concerns.
Aminoglycoside doses for the majority of the patients (53.1%,
n"102/192) did not conform to the recommendations in the na-
tional BPP. Furthermore, a reasonable number of patients (39.6%,
n"76/192) received aminoglycosides for 7 days, which is more
than the recommended duration in most current international
and national guidelines.14 There were also major concerns regard-
ing effective and safe monitoring of aminoglycosides, as indicated
by the lack of baseline or follow-up serum creatinine. In addition,
although TDM of aminoglycosides is not currently performed in
KNH, the HCWs affirmed the need for TDM, but listed knowledge
gaps, lack of willingness and poor coordination as potential
barriers. There were also issues/limitations in the prescription and
administration process of aminoglycosides.
The use of aminoglycosides in the paediatric wards was com-
mon, with an overall prevalence of 8.3%, lower though than the
12.1% reported by Erbay et al.8 and the 33.7% reported by
Prajapati et al.15 This difference could be possibly attributed to con-
cerns about aminoglycoside safety by paediatricians in KNH owing
to the lack of TDM of aminoglycosides. However, differences in the
study settings, and hence the treatment protocols, could also be a
contributing factor.8,15
Of concern is that more than half (50.5%) of the patients did
not receive their aminoglycoside doses within 1 h of the prescribed
dose time, with some patients missing a dose for the entire day.
This, combined with 30.3% of patients missing some aminoglyco-
side doses during the course of therapy, may contribute to
decreased effectiveness and hence treatment failure, increasing
mortality and resistance.
Non-adherence to the Kenyan national protocol and
implications
Incorrect dosing of aminoglycosides (either underdosing or over-
dosing) was one of the major and serious issues identified.
However, it was difficult to establish the direct impact of this on
patients’ clinical outcomes since the majority of these patients
were prescribed an aminoglycoside in combination with other
antibiotics. Consequently, the effect of aminoglycoside underdosing
Figure 1. Flow chart of participant recruitment and response rate.
Table 4. Summary of medication errors in paediatric patients treated
with aminoglycosides at KNH
Error
Ward, n (%)
GPW
(n"44)
NBU
(n"148)
total
(n"192)
Omitted doses 3 (6.8) 29 (19.6) 32 (16.7)
Extra dose 2 (4.6) 22 (14.9) 24 (12.5)
Wrong time 19 (43.2) 78 (57.2) 97 (50.5)
Suspected adverse
drug effects
16 (36.4) 49 (33.1) 65 (33.9)
Wrong combinations 8 (18.2) 6 (4.1) 14 (7.3)
Wrong dose errors
underdose 11 (25) 60 (40.5) 71 (37.0)
overdose 4 (9) 27 (18.2) 31 (16.1)
total 15 (34.1) 87 (58.8) 102 (53.1)
Monitoring errors
no baseline creatinine
levels
1 (0.5) 59 (30.7) 60 (31.2)
no follow-up creatinine
levels
36 (18.7) 138 (71.9) 174 (90.6)
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may not be detected immediately if the causative organism is re-
sponsive to the second antibiotic used in the correct dose; however,
it can be a cause for concern if the organism is not responsive to
the second antibiotic. Furthermore, among aminoglycoside-under-
dosed patients, the switching rate to another antibiotic was higher
in those patients who received an aminoglycoside as monotherapy
compared with an aminoglycoside as combination therapy.
Switching of patients to other antibiotics could be an indicator of
non-response due to underdosing. It was not clear though whether
switching to other antibiotics was necessitated by non-response
or by a change to more appropriate antibiotics.
Incorrect dosing could have been due to the failure to record
the body weight for the majority of patients in the GPWs (52.3%,
n"23/44). Although only 46.9% of patients received doses that
conformed to the national paediatric protocol, this is higher than
the 23% reported by Murgitroyd et al.16 and the 25% by Namazi
et al.,17 indicating that the situation at KNH, although suboptimal,
is better than at some other hospitals. However, some of the rea-
sons listed for non-compliance by Murgitroyd et al.16 included
knowledge gaps and time constraints, which were also highlighted
in our study.
Fourteen (7.3%) patients were on other nephrotoxic drugs,
lower than for Oliveira et al.18 and Gerlach et al.,19 who both
reported 51%. This difference could be attributed to differences in
the study populations since the latter two studies were in adults
who, compared with paediatric patients, have higher chances of
comorbidities and hence a higher likelihood of receiving nephro-
toxic drug combinations. Only 1 patient out of 17 (5.9%) whose
creatinine levels were followed up had nephrotoxicity; on the other
hand, none of the patients whose creatinine levels were followed
up had nephrotoxicity in the study by Rybak et al.,20 as compared
with 1.6% in the study by Contopoulos-Ioannidis et al.21 In the cur-
rent study, all patients were on a once-daily aminoglycoside dos-
ing schedule, which may need reviewing, according to Rybak
et al.,20 alongside the concurrent use of aminoglycosides with
other nephrotoxins.19 Consequently, there is a need to minimize
concurrent use of such drugs, if appropriate, or promote closer
monitoring of patients. Electrolyte imbalance occurred in five
(2.6%) patients. Hyponatraemia and derangement of potassium
levels could be an indicator of nephrotoxicity. Hypernatraemia
could have been a result of diarrhoea or vomiting.22
Currently, TDM at KNH is only undertaken for tacrolimus and
cyclosporine but not for aminoglycosides. Consequently,
aminoglycoside-related toxicity may not be detected early enough
for swift intervention. The current limiting factors for performing
TDM include a lack of aminoglycoside test kits and the contract
agreement that dictates which medicines can be analysed, which
does not include aminoglycosides. However, it is essential to
address and overcome the barriers identified in this study before
the introduction of such a TDM service to ensure effective and effi-
cient uptake and implementation.23–25
Table 5. The current practice for aminoglycoside dosing and monitoring at KNH, staff involvement and need for TDM
Paediatrician
(n"7)
Senior house
officer (n"8)
Pharmacist
(n"4)
Nurse
(n"6)
Laboratory
technologist
(n"3)
Total
(n"28)
Aminoglycoside dosing based on existing
guidelines? (Yes)
1 (14.3) 1 (12.5) 2 (50) 1 (16.7) 0 (0) 5 (17.9)
Aminoglycoside dosing based on weight and
age? (Yes)
3 (42.9) 5 (62.5) 1 (25) 4 (66.7) 0 (0) 13 (46.4)
Aminoglycoside dosing based on renal and liver
function? (Yes)
1 (14.3) 1 (12.5) 2 (50) 0 (0) 0 (0) 4 (14.3)
Is there a system for checking aminoglycoside
dose? (Yes)
2 (28.6) 2 (25) 1 (25) 2 (33.3) 0 (0) 7 (25)
What is the current practice for monitoring aminoglycosides?
not done 2 (28.6) 0 (0) 1 (25) 2 (33.3) 1 (33.3) 6 (21.4)
not sure 4 (57.1) 4 (50) 2 (50) 3 (50) 2 (66.7) 15 (53.6)
renal function test 1 (14.3) 4 (50) 1 (25) 1 (16.7) 0 (0) 7 (25)
Prior involvement in TDM? (Yes) 4 (57.1) 6 (75) 2 (50) 4 (66.7) 0 (0) 16 (57.1)
Have you ever requested for TDM? (Yes) 2 (28.6) 1 (12.5) 1 (25) 0 (0) 0 (0) 4 (14.3)
Do you need training on TDM? (Yes) 3 (42.9) 6 (75) 4 (100) 4 (66.7) 1 (33.3) 18 (64.3)
Values are presented as n (%).
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Figure 2. Opinion of the respondents on what can prevent effective im-
plementation of a protocol on aminoglycoside dosing and monitoring in
KNH.
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Identified gaps and potential future strategies and
implications
The current study findings clearly indicate significant gaps in
the practice of aminoglycoside use. These findings could form
the basis for suggested strategies to improve the future use of
aminoglycosides to optimize patients’ safety and quality of care.
This could involve including aminoglycosides in future antimicro-
bial stewardship programmes (ASPs), which might include clear
local protocols for prescribing, administrating and monitoring ami-
noglycosides, including signs of toxicity. These could incorporate
clear instructions on how to calculate the correct aminoglycoside
dose, initially and subsequently, based on patients’ age and
weight.26 An online calculator or a mobile app could also be used
to help calculate the correct initial aminoglycoside dose.27 One of
the potential ASPs could be a standard patient chart for prescrib-
ing, administrating and monitoring of aminoglycosides with brief
information including the maximum duration of 3–4 days.13 In the
case of a longer treatment duration, advice should be sought from
microbiologists, infectious disease physicians and antimicrobial
pharmacists, including evidence-based guidelines on switching IV
aminoglycosides to oral antibiotics when longer treatment is
needed as longer treatment is associated with high toxicity.28,29
This is particularly important in KNH given that a longer aminogly-
coside duration of 7 days was observed in nearly half of the
patients (39.6%, n"76/192). It is also critical to have effective im-
plementation strategies to ensure optimal uptake by clinicians,
such as academic detailing, educational sessions and clinicians’
active engagement in the protocol design, development and im-
plementation.30–32 These suggestions would improve the quality
and safety of aminoglycoside use not only in Kenya but also in
other African countries with similar settings.
Strengths and limitations of the study
We are aware of several limitations. One of the challenges was in-
complete medical records. Unavailability of TDM and minimal
follow-up of creatinine levels was a limitation to monitoring
patients for aminoglycoside toxicity. There could also be misclassi-
fication of patients for nephrotoxicity.
Whilst the questionnaire was not validated in this study, it
has been designed and validated in other African countries with
similar settings to Kenya.12 There was a low response rate by the
paediatrician specialists, although it is unlikely that there are major
differences in the perceptions of responders and non-responders
since the main reason given for non-participation was time
constraints. Overall, interviewing 28 participants appears to be an
acceptable number in qualitative studies, with evidence indicating
that level of thematic saturation is achieved in most cases after
interviewing16 participants.33
One strength was the use of both quantitative and qualitative
approaches. The qualitative findings complemented/integrated
the quantitative findings, the latter highlighting suboptimal prac-
tice in aminoglycoside dosing with reported potential aminoglyco-
side toxicity and adverse effects that indicate the need for and
importance of having robust monitoring of aminoglycoside use,
ideally through TDM. However, to perform TDM, it is crucial to
understand the current situation at KNH in terms of facilitators and
barriers for introducing TDM, most of which are provided by the
qualitative findings.
Conclusions
Aminoglycoside use appeared to be common among paediatric
patients admitted to KNH. Adherence to the national treatment
guideline was suboptimal and raises concerns around potential,
avoidable harm to patients. Inadequate monitoring of paediatric
patients on aminoglycosides is another matter of concern that
requires urgent attention. The identified gaps highlight the need
for potential strategies to improve the practice of aminoglycoside
use including the development of ASPs. This situation analysis
study has identified gaps and areas for quality improvement
interventions, with the study findings serving as a baseline for any
future interventions.
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